ARB vs ACE Inhibitor for Cardiovascular Prevention: Same Protection, Better Tolerability, and Why Half-Life Matters

For a decade we taught that ACE inhibitors save lives and ARBs are for when patients cough or have angiodema as sides effects of ACEI. That teaching is outdated for hypertension and vascular prevention.

1. Same efficacy

The ONTARGET trial changed practice. 25,620 patients with vascular disease or high-risk diabetes were randomized to ramipril 10mg, telmisartan 80mg, or both. The primary outcome - CV death, MI, stroke, or heart failure hospitalization - was 16.5% with ramipril vs 16.7% with telmisartan, RR 1.01. Telmisartan was non-inferior and conserved 95% of ramipril's benefit. Combination added no efficacy, only more hypotension, renal dysfunction and hyperkalemia.

Meta-analyses since have confirmed it:

27 RCTs, 125,330 high-risk patients without heart failure: no difference between ACE and ARB for CV death, MI, or stroke.

>2.9 million patients in real-world data: no difference for acute MI, heart failure, stroke or composite CV events.

Cochrane review of ACE vs ARB for primary hypertension, 9 trials, 11,007 patients: total mortality RR 0.98 [0.88-1.10], total CV events RR 1.07 [0.96-1.19], CV mortality RR 0.98 [0.85-1.13] - no evidence of difference.

For high CV risk without HFrEF, efficacy is a tie.

2. Fewer adverse events with ARBs

ACE inhibitors block kininase II. Bradykinin accumulates. That gives you the dry, persistent cough and angioedema.

Across large datasets, ACE inhibitors are 3.3 times more likely to cause angioedema and 32% more likely to cause cough vs ARBs. Cochrane found ARBs had 17% fewer withdrawals due to adverse events, RR 0.83, ARR 1.8%, NNT 55 over 4.1 years to prevent one withdrawal, driven almost entirely by cough.

In ONTARGET, telmisartan was better tolerated. Better tolerability is better real-world effectiveness.

3. Not all ARBs last 24 hours

Half-life decides trough-to-peak ratio and early-morning coverage, when most CV events occur.

Losartan: 2h parent, 6-9h active metabolite

Eprosartan: 5-7h

Valsartan: 7h

Azilsartan: 11h

Irbesartan: 11-15h

Candesartan: 9-13h

Olmesartan: 12-14h

Telmisartan: 24h

Olmesartan is similar to azilsartan, candesartan and irbesartan and is surpassed only by telmisartan. Losartan, eprosartan and valsartan are short half-life ARBs.

Head-to-head: Telmisartan 80mg significantly reduces 24-hour BP vs losartan 50mg, with the largest difference in the last 6 hours of the dosing interval - the critical early-morning period. Telmisartan provides smoother, more consistent 24-hour control and better early-morning BP control than losartan/HCTZ.

Telmisartan is also the only ARB with a 24-hour half-life, insurmountable AT1 binding, and partial PPAR-gamma activity. Olmesartan, is the second longest at ∼13h, with the highest AT1 selectivity and very potent BP lowering.

Losartan works, but once-daily it often doesn't cover 24 hours and many patients need BID dosing.

Practical take

For cardiovascular prevention: ACE = ARB for outcomes. ARB > ACE for tolerability. And within ARBs, choose a true 24-hour agent - telmisartan or olmesartan - over losartan if you want forgiving once-daily coverage and morning protection.

References

Results of the ONTARGET and TRANSCEND studies - ONTARGET non-inferiority - https://pmc.ncbi.nlm.nih.gov/articles/PMC2672448/

Cochrane: ACE inhibitors versus ARBs for primary hypertension - https://www.cochrane.org/CD009096/HTN_angiotensin-converting-enzyme-ace-inhibitors-versus-angiotensin-receptor-blockers-for-primary-hypertension

ARB half-life comparison - olmesartan 12-14h, telmisartan 24h, losartan 4-6h - https://inpharmd.com/inquiries/10132

Telmisartan vs losartan 24h BP control and early morning benefit - https://www.droracle.ai/articles/106939/can-i-switch-from-telmisartan--hctz-to-losartan--hctz-

ACE vs ARB safety - fewer cough/angioedema with ARB - https://consultqd.clevelandclinic.org/ace-inhibitor-and-arb-therapy-practical-recommendations

2.9M patient observational study - similar CV outcomes, lower AE with ARB - https://www.uspharmacist.com/article/ace-inhibitors-versus-arbs-1